A multicenter retrospective study assessing venetoclax for Chronic lymphocytic leukemia (CLL)
Latest Information Update: 06 Jan 2021
Price :
$35 *
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 06 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology